CoVPN 3501/BLAZE-2: Eli Lilly’s Bamlanivimab (LY-CoV555) Antibody

Read the latest news releases:

• Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
• Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19

BLAZE-2 is testing monoclonal antibodies. It is enrolling staff and residents in skilled nursing and assisted living facilities with a high risk of exposure to SARS-CoV-2. The study questions are:

• Does the antibody prevent the acquisition of SARS-CoV-2?
• Does the antibody help to prevent the development of more severe COVID-19, or does it reduce the symptoms?

The study is being conducted in the United States with up to 2,400 participants. Monoclonal antibodies are designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. Monoclonal antibodies were developed in a lab by the pharmaceutical company Eli Lilly. Monoclonal antibodies cannot give you SARS-CoV-2, nor will they make you sick with COVID-19.

Visit blaze2study.com or ClinicalTrials.gov - NCT04497987 for additional details about the Eli Lilly monoclonal antibody clinical study to prevent COVID-19. A Spanish version of the website is available at blaze2study.com/es-us. You may also call the BLAZE-2 Call Center at 800-953-5234 or 718-210-9713 from 9 a.m. to 5:30 p.m. Eastern Time Monday through Friday.